Palatin Technologies (PTN) said Friday that topline results from its phase 2 study of PL8177 in patients with active ulcerative colitis showed clinical remission in 33% of treated patients after eight weeks of treatment, while none in the placebo group achieved remission.
Nine of the 12 patients received PL8177, and 78% of the treated group showed a clinical response, according to the company.
CEO Carl Spana said the strong data, along with prior findings, supports ongoing licensing discussions with multiple pharmaceutical companies.
Shares of Palatin were down 7.6% in recent trading.
Price: 0.65, Change: -0.05, Percent Change: -7.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。